Sei Investments Co. grew its holdings in Novartis AG (NYSE:NVS) by 5.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 1,273,150 shares of the company’s stock after purchasing an additional 63,402 shares during the period. Sei Investments Co.’s holdings in Novartis were worth $120,624,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. Timber Creek Capital Management LLC boosted its holdings in shares of Novartis by 0.3% during the 4th quarter. Timber Creek Capital Management LLC now owns 37,818 shares of the company’s stock valued at $3,581,000 after acquiring an additional 105 shares in the last quarter. First Hawaiian Bank boosted its holdings in shares of Novartis by 1.6% during the 4th quarter. First Hawaiian Bank now owns 7,109 shares of the company’s stock valued at $674,000 after acquiring an additional 113 shares in the last quarter. Baystate Wealth Management LLC boosted its holdings in shares of Novartis by 22.5% during the 3rd quarter. Baystate Wealth Management LLC now owns 625 shares of the company’s stock valued at $54,000 after acquiring an additional 115 shares in the last quarter. Watch Point Trust Co boosted its holdings in shares of Novartis by 0.3% during the 4th quarter. Watch Point Trust Co now owns 42,657 shares of the company’s stock valued at $4,039,000 after acquiring an additional 115 shares in the last quarter. Finally, Leavell Investment Management Inc. boosted its holdings in shares of Novartis by 3.9% during the 3rd quarter. Leavell Investment Management Inc. now owns 3,134 shares of the company’s stock valued at $272,000 after acquiring an additional 119 shares in the last quarter. Institutional investors own 10.61% of the company’s stock.

Several equities research analysts recently weighed in on NVS shares. ValuEngine raised Novartis from a “sell” rating to a “hold” rating in a report on Saturday, October 19th. Cowen reissued a “buy” rating and set a $100.00 price objective on shares of Novartis in a report on Friday, October 25th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $93.34.

NVS traded down $0.14 during midday trading on Friday, hitting $97.63. 1,058,244 shares of the company were exchanged, compared to its average volume of 1,886,027. The firm has a market capitalization of $223.77 billion, a P/E ratio of 19.33, a P/E/G ratio of 2.14 and a beta of 0.64. Novartis AG has a 1-year low of $74.97 and a 1-year high of $99.84. The firm’s 50 day moving average price is $95.15 and its 200-day moving average price is $90.83. The company has a quick ratio of 0.83, a current ratio of 1.04 and a debt-to-equity ratio of 0.40.

The business also recently announced an annual dividend, which will be paid on Thursday, March 12th. Shareholders of record on Wednesday, March 4th will be issued a dividend of $3.0425 per share. The ex-dividend date is Tuesday, March 3rd. This is an increase from Novartis’s previous annual dividend of $2.86. This represents a yield of 2%. Novartis’s payout ratio is presently 35.11%.

Novartis Profile

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.

See Also: Outstanding Shares, Buying and Selling Stocks

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.